{"entity":{"id":"sumit-gupta","kind":"person","name":"Sumit Gupta","aka":[],"tldr":"Led COG AALL1731, which showed adding blinatumomab to chemotherapy improves survival for children with standard-risk leukaemia.","summary":"Sumit Gupta was study chair of Children's Oncology Group AALL1731, the randomised trial showing that adding the CD19 bispecific blinatumomab to chemotherapy dramatically improves disease-free survival in children with newly diagnosed standard-risk B-cell acute lymphoblastic leukaemia, the largest advance in front-line childhood ALL in decades. He also studies disparities and outcomes in paediatric cancer at SickKids.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gupta%20S%5BAuthor%5D%20blinatumomab%20AALL1731"}],"tags":["paediatric","all","immunotherapy"],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":["t-cell-engager"],"targets":["cd19","cd3"],"drugs":["blinatumomab"],"companies":[],"institutions":["sickkids"],"pathways":[],"terms":[],"trials":["aall1731"],"people":[],"bottlenecks":[],"keyPapers":["paper-aall1731-blinatumomab-children-nejm-2025"],"journals":["cancer-wiley"],"dependsOn":[],"notes":[],"role":"Staff Oncologist and Senior Scientist, The Hospital for Sick Children (SickKids), Toronto","institutionId":"sickkids","specialisms":["Paediatric acute lymphoblastic leukaemia","Immunotherapy","Health outcomes research","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gupta%20S%5BAuthor%5D%20blinatumomab%20AALL1731"}],"papers":[{"title":"Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children (AALL1731)","journal":"NEJM","year":2025},{"title":"Pediatric cancer outcomes and socioeconomic status: population-based studies","journal":"Cancer","year":2016},{"title":"Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL","journal":"New England Journal of Medicine","year":2025,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AALL1731%20blinatumomab%20standard-risk%20B-ALL%20children%20Gupta%20NEJM%202025"}]},"route":"/people/sumit-gupta/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"}],"technology":[{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"},{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"}],"drug":[{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/"}],"institution":[{"id":"sickkids","kind":"institution","name":"The Hospital for Sick Children (SickKids)","route":"/institutions/sickkids/"}],"trial":[{"id":"aall1731","kind":"trial","name":"COG AALL1731","route":"/trials/aall1731/"}],"paper":[{"id":"paper-aall1731-blinatumomab-children-nejm-2025","kind":"paper","name":"Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL","route":"/key-papers/paper-aall1731-blinatumomab-children-nejm-2025/"}],"journal":[{"id":"cancer-wiley","kind":"journal","name":"Cancer","route":"/journals/cancer-wiley/"}]}}